Velhos e novos anticoagulantes orais. Perspetiva farmacológica

Keisu, 2010, Drug-induced liver injury in humans: the case of ximelagatran, Handb Exp Pharmacol, 196, 407, 10.1007/978-3-642-00663-0_13 Harenberg, 2011, New Anticoagulants - Promising and Failed Developments, Br J Pharmacol Paliwal, 2011, Recent advances in search of oral heparin therapeutics, Med Res Rev Fareed, 2012, Old versus new oral anticoagulants: focus on pharmacology, Annu Rev Pharmacol Toxicol, 52, 79, 10.1146/annurev-pharmtox-010611-134633 Baughman, 1998, Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans, Circulation, 98, 1610, 10.1161/01.CIR.98.16.1610 Arbit, 2006, Oral heparin: status review, Thromb J, 4, 6, 10.1186/1477-9560-4-6 Kim, 2007, A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study, J Control Release, 123, 155, 10.1016/j.jconrel.2007.08.007 Eriksson, 2009, Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development, Clin Pharmacokinet, 48, 1, 10.2165/0003088-200948010-00001 Rupprecht, 2010, Clinical pharmacology of direct and indirect factor Xa inhibitors, Drugs, 70, 2153 Eriksson, 2011, Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism, Ann Rev Med, 62, 41, 10.1146/annurev-med-062209-095159 Macedo, 2006, Modificadores da hemostase, 444 Valentine KA, Hull RD. Therapeutic use of warfarin. UpToDate, 2011. http://www.uptodate.com/contents/therapeutic-useof-warfarin?source=search_result&search=warfarin&selectedTitle=4%7E150 (accessed November, 2011). Varfine®. Resumo das características do medicamento, 2006: http://www.infarmed.pt/infomed/download_ficheiro.php?med_id=9007&tipo_doc=rcm (accessed December, 2011). Sintrom®. Resumo das características do medicamento, 2007: http://www.infarmed.pt/infomed/download_ficheiro.php?med_id=7906&tipo_doc=rcm (accessed December, 2011). Ansell, 2008, Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), Chest, 1336, 160S, 10.1378/chest.08-0670 Keeling, 2011, Guidelines on oral anticoagulation with warfarin - fourth edition, Br J Haematol, 154, 311, 10.1111/j.1365-2141.2011.08753.x Bauersachs, 2012, Use of anticoagulants in elderly patients, Thrombosis Research, 129, 107, 10.1016/j.thromres.2011.09.013 Alving, 1985, Hereditary warfarin resistance. Investigation of a rare phenomenon, Arch Intern Med, 145, 499, 10.1001/archinte.1985.00360030147025 Bodin, 2008, Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans, J Thromb Haemost, 6, 1436, 10.1111/j.1538-7836.2008.03049.x Visser, 2002, Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants, Thromb Haemost, 88, 705, 10.1055/s-0037-1613289 Fischer, 2010, Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study, Arch Intern Med, 170, 617, 10.1001/archinternmed.2010.37 Teichert, 2011, Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment, Br J Haematol, 153, 379, 10.1111/j.1365-2141.2011.08633.x Valentine KA, Hull RD. Outpatient management of oral anticoagulation. UpToDate, 2011a. http://www.uptodate.com/contents/outpatient-management-of-oral-anticoagulation?source=search_result&search=warfarin&selectedTitle=14%7E150 (accessed November, 2011). Valentine KA, Hull RD. Correcting excess anticoagulation after warfarin. UpToDate, 2011b. http://www.uptodate.com/contents/correcting-excess-anticoagulation-after-warfarin?source=search_result&search=warfarin+reversal&selectedTitle=1%7E13 (accessed November, 2011). Bavisotto, 2011, Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants, J Clin Pharmacol, 51, 561, 10.1177/0091270010370588 Ellis, 2009, The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation, Circulation, 120, 1029, 10.1161/CIRCULATIONAHA.109.856120 Bowersox, 2010, Antithrombotic activity of the novel oral anticoagulant. Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models, Thromb Res, 126, e383, 10.1016/j.thromres.2010.08.025 Steffel, 2011, Novel drug anticoagulants: focus on stroke prevention and treatment of venous-embolism, Eur Heart J, 32, 1968, 10.1093/eurheartj/ehr052 Sanford, 2008, Dabigatran etexilate, Drugs, 68, 1699, 10.2165/00003495-200868120-00007 6. Pradaxa??. Resumo das caracter??sticas do medicamento, 2011 7. http://www.ema.europa.eu/docs/pt_PT/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf (accessed December, 2011). Eisert, 2010, Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin, Arterioscler Thromb Vasc Biol, 30, 1885, 10.1161/ATVBAHA.110.203604 European Medicines Agency. European Medicines Agency updates on safety of Pradaxa (press release), EMA/CHMP/903767/2011-18 November 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/11/WC500117818.pdf (accessed January, 2012). Eerenberg, 2011, Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects, Circulation, 124, 1573, 10.1161/CIRCULATIONAHA.111.029017 Cotton, 2011, Acutely injured patients on dabigatran, N Engl J Med, 365, 2039, 10.1056/NEJMc1111095 Marques da Silva, 2010, Características farmacodinâmicas e farmacocinéticas dos inibidores directos do Factor Xa: foco no rivaroxabano, Rev Port Cardiol, 29, 15 Samama, 2011, The mechanism of action of rivaroxaban — an oral, direct Factor Xa inhibitor— compared with other anticoagulants, Thrombosis Research, 127, 497, 10.1016/j.thromres.2010.09.008 Perzborn, 2010, Rivaroxaban: a new oral factor Xa inhibitor, Arterioscler Thromb Vasc Biol, 30, 376, 10.1161/ATVBAHA.110.202978 Misselwitz, 2011, The discovery and development of rivaroxaban, Ann N Y Acad Sci, 1222, 64, 10.1111/j.1749-6632.2011.05971.x Perzborn, 2011, The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor, Nat Rev Drug Discov, 10, 61, 10.1038/nrd3185 9. Xarelto??. Resumo das caracter??sticas do medicamento, 2011 10. http://www.ema.europa.eu/docs/pt_PT/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf (accessed December, 2011). Ieiri, 2011, Functional Significance of Genetic Polymorphisms in P-glycoprotein (MDR1, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2), Drug Metab Pharmacokinet Kubitza, 2008, Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation, Drug Saf, 31, 67, 10.2165/00002018-200831010-00006 11. Eliquis??. Resumo das caracter??sticas do medicamento, 2011 12. http://www.ema.europa.eu/docs/pt_PT/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf (accessed December, 2011). Camm, 2011, Edoxaban: a new oral direct factor Xa inhibitor, Drugs, 71, 1503, 10.2165/11595540-000000000-00000